|
Post by slugworth008 on Jan 19, 2018 21:25:18 GMT -5
Wow:-) I wonder what those flags mean? I can't wait to see the flag of the "New California"
|
|
|
Post by nylefty on Jan 19, 2018 23:10:16 GMT -5
The flag on the upper right is the state flag of New Mexico, where Vdex has posted at least one job opening. The flag on the lower left is the state flag of Ohio, where a Vdex office is "coming." The flag on the lower right is the state flag of Missouri, so it looks like Vdex will be there soon.
|
|
|
Post by kc on Jan 19, 2018 23:15:31 GMT -5
The bottom right flag is the state of Missouri Show me state
|
|
|
Post by mango on Jan 19, 2018 23:31:51 GMT -5
And will they release the data if it turns out the humalog arm did better than the afrezza arm? My point is that the study declares itself to be a pilot study lasting only a month, which automatically means it won't be of any use to impress insurers. Also, the afrezza group appears to get a lot more attention in terms of consultations during the study than the humalog group which appears to get none; I suspect MDs and diabetic researchers will find fault with that. To me it would have been more rational and cheaper to do just an afrezza alone pilot study first to see if, in fact, the drug does produce better PPGE, etc, with the CGM and if it did and if there was an impressive enough difference, then move onto a bigger,longer study comparing to humalog. this study has continuous glucose monitors on everybody. The study will ALLOW physicians to look at Afrezza on a continuing glucose monitor. I see the results on Twitter everyday. Afrezza users posting their blood sugars via CGMs. Same thing as this trial. A CGM doesn't know the difference from "real life" and a "clinical trial". Real life shows that Afrezza restores glucose homeostasis. For example... a PWD that uses Afrezza and Tresiba posts pictures like this all the time.
|
|
|
Post by olebob1 on Jan 20, 2018 8:48:39 GMT -5
And will they release the data if it turns out the humalog arm did better than the afrezza arm? My point is that the study declares itself to be a pilot study lasting only a month, which automatically means it won't be of any use to impress insurers. Also, the afrezza group appears to get a lot more attention in terms of consultations during the study than the humalog group which appears to get none; I suspect MDs and diabetic researchers will find fault with that. To me it would have been more rational and cheaper to do just an afrezza alone pilot study first to see if, in fact, the drug does produce better PPGE, etc, with the CGM and if it did and if there was an impressive enough difference, then move onto a bigger,longer study comparing to humalog. this study has continuous glucose monitors on everybody. The study will ALLOW physicians to look at Afrezza on a continuing glucose monitor. Fast track this case (study) to SCOTUS. I understand there is one Judge in particular that may be interested in the results. Bring a case against UC for early release. Vreedom for the Judge.
|
|
|
Post by sayhey24 on Jan 20, 2018 9:49:20 GMT -5
This is primarily a time in range study. If you can show better time in range using a CGM for a month why would anyone think you can't do it for two or three months or even three years? The answer is because results vary over time. There is a known effect in studies where people do better than in real life because they have more resources and coaching available. To counter that you run longer studies. I was looking a a study the other days where the two results were radically different for the first month or so, but by the end of month three were neck and neck. Insurers are well aware of these possibilities and a month study will not change anything. What it will do is let Mannkind design a better long term follow on trial. The data will help pin down what behaviors worked best and next time they can focus on those to improve the outcome in the next study. You are correct but thats old school thinking.. The concept of Cloud CGM is 24/7 monitoring and coaching. Thats the Onduo model. What we expect to see in the STAT is week by week better use of afrezza and TIR. This is all recorded and monitored. Unlike old school trials there is no guessing. If Onduo's model is correct they should be able to get even better results after a few months. If the results are as good as some think, let the insurance companies all fund their own private studies. They have a hell of a lot more money than MNKD. Heck, Apple is doing a bunch of "secret stuff". Let them fund some studies too. MNKD has the "Holy Grail", now its time for others to pay.
|
|
|
Post by sayhey24 on Jan 20, 2018 9:53:01 GMT -5
This is primarily a time in range study. If you can show better time in range using a CGM for a month why would anyone think you can't do it for two or three months or even three years? United Health, Aetna and others want to make money. One of their biggest cost drivers is diabetes. These same companies have pilots with Dexcom, Libre, Apple and fitbit to better monitor. The problem after you monitor is you have to do something. Now our AACE friends say here www.aace.com/sites/all/files/diabetes-algorithm-executive-summary.pdf Insulin is the most potent antihyperglycemic agent on page 8. Why wouldn't you use the best? Well, until afrezza there was a huge concern about hypoglycemia. Thats not the case with afrezza. Moreover we are seeing more results coming in which are showing keeping the T2 in a near non-diabetic range not only stops but can even reverse progression. What insurance company that wants to save money would not be interested in a treatment which has minimal hypoglycemia risk and can reverse diabetes and save them a ton of money in the long run? Where I come from money talks. If you can provide a near cure which is very safe I think they will be interested. After 3 years and no lung issues the waiting time is over, I think they want to play ball. Now, we already know from years and years that Novolog is not great at time in range. We also know from over 60 studies Al Mann did and the clamp study that afrezza has a profile which mimics the natural pancreas and MNKD used that clamp data for the label change. Its not a question of is afrezza faster than Novolog. That ship has sailed. Its on the label. Its a question of proper timing with Novolog and the fact that stacking it is unpredictable. Not so with afrezza, in fact second and even third dosing is encouraged. For years and years some of the best tried to make Novolog/Humalog keep better time in range and they failed. Why should anyone think the trial participants can do better than the experts? Maybe they can but it would be surprising. Very well stated, I am living it each day now!! Each day my daily avg. is improving, if I need a correction dose, no problemo, it's a beautiful thing if I must say so myself....feel like I'm on my own T2 STAT study Maybe you want to tell your story on Tudiabetes. They seem to be banning afrezza again as there is some effort to not want to have people hear about it there.
|
|
|
Post by agedhippie on Jan 20, 2018 9:56:21 GMT -5
Very well stated, I am living it each day now!! Each day my daily avg. is improving, if I need a correction dose, no problemo, it's a beautiful thing if I must say so myself....feel like I'm on my own T2 STAT study Maybe you want to tell your story on Tudiabetes. They seem to be banning afrezza again as there is some effort to not want to have people hear about it there. What happened on Tudiabetes ?
|
|
|
Post by sayhey24 on Jan 20, 2018 13:08:18 GMT -5
It appears a renewed effort by BP to pressure TU admins to pull pro afrezza posts. They are calling it promoting a vendor and advertising. If I remember correctly this was done 3 years ago calling the pro-afrezza people paid reps for MNKD. If I also remember correctly it resulted in this site forum.fudiabetes.org/VDex put out their updated white paper. They are calling it a 12 month study. They are making some extraordinary claims about hypoglycemia. IMO, if they are half right what they are claiming is huge.
|
|
|
Post by babaoriley on Jan 20, 2018 15:57:12 GMT -5
The article written by Ginger which mannmade recently posted in the Articles subsection should be posted on Tudiabetes.
|
|
|
Post by xanet on Jan 20, 2018 16:18:56 GMT -5
If Humalog claims victory, you can dismiss it. The STAT trial pitted Afrezza against Novolog's insulin aspart (chuckle). Teasing aside (humbly noted) the advantage of going against Novolog is that MannKind can claim to have beat the world's #1 prandial insulin. That's the kind of data that marketing executives truly relish! Me, too! has anyone figured out with any confidence when this data will be released? I can not imagine they would hold it when it is needed so badly unless it is locked/embargoed. Can it be used behind the scenes for partner/insurance negotiations if not presented until June? As noted in a previous thread, I contacted a colleague at the research center, and they will present the data at ADA. I don't know what their specific protocols are, but it is common to unofficially share unpublished preliminary results with interested parties. They just have to be careful to safeguard the data and not violate any rules. Most likely the people who "need to know" have a good idea of the results. And most of us are not on that short list.
|
|
|
Post by InvesterSam on Jan 21, 2018 19:24:58 GMT -5
Wow:-) I wonder what those flags mean? I did calculate number of diabetes per square mile of area as (% diabetes in each state) x (state population) / (area). It does not seem MO and NM are ideal places. Rank State Diabetes #/sq mile
1 Washington, D. C. 678 2 New Jersey 93 3 Rhode Island 67 4 Connecticut 63 5 Massachusetts 58 6 Maryland 50 7 Delaware 38 8 New York 37 9 Florida 34 10 Pennsylvania 31 11 Ohio 29
12 California 23
28 Missouri 10
45 New Mexico 2
|
|
|
Post by boca1girl on Jan 21, 2018 19:40:21 GMT -5
NM has a high % of Native Americans. They have a high incedence of diabetes.
NM is not a densely populated state. In the areas of high population, there is a high percentage of the population with diabetes.
|
|
|
Post by goyocafe on Jan 21, 2018 19:44:17 GMT -5
NM has a high % of Native Americans. They have a high incedence of diabetes. NM is not a densely populated state. In the areas of high population, there is a high percentage of the population with diabetes. Otherwise known as an oasis. 🙂
|
|
|
Post by careful2invest on Jan 21, 2018 21:24:40 GMT -5
The flag on the upper right is the state flag of New Mexico, where Vdex has posted at least one job opening. The flag on the lower left is the state flag of Ohio, where a Vdex office is "coming." The flag on the lower right is the state flag of Missouri, so it looks like Vdex will be there soon. Lefty, Do you, or anyone here, know what city in Ohio is chosen to get the new Vdex office? And when? Thanks! GLTA!
|
|